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Abstract 
Background: In 2011/2012, the European Centre for Disease Prevention and Control 
(ECDC) conducted the first Europe-wide point prevalence survey (PPS) of healthcare-
associated infections (HAIs) in acute care hospitals. We conducted an analysis of specifically 
paediatric data from this ECDC PPS. 
Methods: Patients present on the ward at 8:00 AM on the day of the survey and not 
discharged at the time of the survey were included. Data were collected by locally trained 
healthcare workers according to a patient-based or unit-based protocol. HAI prevalence and 
distribution of HAI-types among countries and clinical settings were the main outcomes. HAI 
prevalence and its corresponding 95% confidence intervals, we calculated by clustering at 
the hospital and country level.  
Findings: In total, 17,273 children from 29 countries were analysed. Seven-hundred-seventy 
HAIs were reported in 726 children corresponding to a prevalence [95%CI] of 4.2% [3.7-4.8] 
with bloodstream infections (BSIs) being the leading type (343/770), followed by infections of 
the lower respiratory tract (171/770), gastrointestinal infections (64/770), eye ear nose and 
throat infections (55/770), urinary tract infections (37/770), and surgical site infections 
(34/770). HAI prevalence was highest in paediatric intensive care units (122/788) and 
neonatal intensive care units (244/2283). Neonates and infants in their first 11 months of life, 
ultimately and rapidly fatal McCabe scores, prolonged length of stay, and the use of invasive 
medical devices were independent risk factors for HAI. Three-hundred-ninety-two 
microorganisms were reported for 342 HAIs, with Enterobacteriaceae being the most 
frequently reported (113/392).  
Interpretation: This analysis represents the largest multi-national study on HAI prevalence 
in children. BSI was the most frequent type of HAI. Infection prevention and control strategies 
in children should focus on BSI prevention, particularly among neonates and infants. 
Funding: The ECDC PPS 2011-2012 was coordinated by ECDC and performed by each 
EU/EEA Member State with its own funding. ECDC funded several meetings of experts and 
Member State contact points to develop the methodology, provide training, and discuss 
results. No specific funding was provided by ECDC for this analysis of paediatric data. 
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Research in context 
Evidence before this study 
Point prevalence surveys have been used for the surveillance of healthcare-associated 
infections (HAIs) for many years. We searched PubMed with the search terms  
“cross infection” [MeSH], “healthcare-associated infection$”, “nosocomial infection$”, and 
“hospital-acquired infection$”) in combination with “prevalence”, with age restriction (0-18 
years) but without time restriction (up to June 2016). Of 928 titles and abstracts, 15 reports 
were multicentre national or multi-national prevalence surveys in high-income countries. One 
report was the pilot testing of the European Centre for Disease Prevention and Control 
(ECDC) point prevalence survey in 2010. Two national surveys (UK-Scotland, Poland) were 
part of the ECDC point prevalence survey 2011/2012 reported in this study. Most surveys 
were performed in acute-care adult or mixed adult-paediatric healthcare settings. Only one 
multi-national point prevalence survey reported paediatric data. Between 1983 and 1987, the 
World Health Organization conducted a multinational prevalence survey in 47 hospitals of 14 
high- and upper-middle-income countries showing that, among a total of 28,861 patients, 
3147 were children with a pooled HAI prevalence in children of 8.7%. Nine surveys were 
conducted in a general population in which children were included, two addressed neonatal 
intensive care only, and one was performed in general paediatric wards. Finally, one study in 
the UK and Ireland focused exclusively on respiratory tract infections in children. 
 
Added value of this study 
This analysis of paediatric data from the ECDC point prevalence survey 2011/2012 
represents the largest multi-national study on HAI prevalence in children. The adjusted 
prevalence [95%CI] was 4.2% [3.7-4.8%]. The survey confirms that the burden of HAIs is the 
highest in the first year of life and in neonatal and paediatric intensive care units. 
Bloodstream infection was the most common type of HAI, not only in neonates and infants in 
their first 11 months of life but throughout childhood. With older age, infections such as lower 
respiratory tract infections or surgical site infections were more common. The variation of HAI 
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prevalence among European countries (1.2-10.4%) could neither be explained by the 
distribution of paediatric settings, nor did it follow a geographical or socio-economic pattern. 
Only five countries were statistically significant high or low outliers. 
 
Implications of all the available evidence 
Given the high prevalence of HAIs among neonates and small infants, in both neonatal and 
paediatric intensive care settings, and bloodstream infection being the most common type of 
HAI, infection prevention and control should focus on the prevention of bloodstream 
infections in the youngest age groups, particularly in neonatal and paediatric intensive care 
units.  
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Introduction 
For many years, point prevalence surveys (PPSs) have been used for healthcare-associated 
infection (HAI) surveillance.1 The pioneering Study on the Efficacy of Nosocomial Infection 
Control (SENIC) project, initiated in the 1970s by the US Centers for Disease Control and 
Prevention (CDC) used repeated PPSs to study the benefit of establishing infection 
prevention and control (IPC) teams in US hospitals.2 In the following years, the US National 
Nosocomial Infection Surveillance (NNIS) system established prospective HAI surveillance in 
intensive care units, which was taken up by national surveillance networks in other countries. 
Incidence surveillance has become the gold standard for HAI surveillance in high-risk areas 
such as intensive care, oncology, or neonatal care, and for selected HAIs such as ventilator-
associated pneumonia, catheter-associated urinary tract infections, and catheter-associated 
bloodstream infections. However, incidence surveillance is almost never performed for all 
HAI types because it is cumbersome and resource demanding. PPSs offer an alternative to 
estimate the hospital-wide burden of HAIs within a reasonable budget.1 Thus, it can be 
applied to a wider range of settings including institutions with limited resources and allows for 
broadening the comparison of HAI rates across a wider range of socio-cultural contexts. In 
July 2008, the coordination of the EU-funded network Improving Patient Safety in Europe 
(IPSE) and its HAI surveillance component (previously Hospitals in Europe Link for Infection 
Control through Surveillance - HELICS) were transferred to the European Centre for Disease 
Prevention and Control (ECDC) to form a new Healthcare-Associated Infections surveillance 
Network (HAI-Net), which, in 2009, started planning the first EU-wide PPS about HAI and 
antimicrobial use in European acute care hospitals.3 
In 2011–2012, the EU Member States, Iceland, Norway and Croatia participated in 
this ECDC PPS. Data on 273,753 patients from 1149 hospitals were submitted to ECDC and, 
in order to obtain similar precision in HAI prevalence estimates for all participating countries, 
a representative sub-sample of hospitals was drawn from the data for countries that were 
overrepresented such as Belgium, Portugal, and Spain. A total of 231,459 patients from 947 
hospitals remained in the final ECDC PPS database.3 The prevalence of patients with one or 
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more HAIs was 6.0% (country range 2.3–10.8%).3 When extrapolated to the average daily 
number of occupied beds per country, the adjusted overall HAI prevalence was estimated at 
5.7% [95% confidence interval (95%CI) 4.5–7.4%]. The most frequent types of HAI were 
lower respiratory tract infections (LRTIs, i.e. pneumonia 19.4% and other lower respiratory 
tract infections 4.1%), followed by surgical site infections (SSIs; 19.6%), urinary tract 
infections (UTIs; 19.0%), bloodstream infections (BSIs; 10.7%), and gastro-intestinal 
infections (GIs; 7.7%).3 
We report the results of an analysis of data from paediatric patients that were enrolled 
in the ECDC PPS. The objectives of this study were: a) to calculate HAI prevalence among 
hospitalised children of different age groups in Europe; b) to describe the distribution of HAI 
types in different paediatric settings and age groups; and c) to determine risk factors for HAI 
among hospitalised children in Europe.  
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Methods 
Data reporting was done according to the STROBE Guidelines.4 National PPS contact points 
in EU Member States, Iceland, Norway and Croatia agreed to organise a PPS of HAI and 
antimicrobial use in acute care hospitals in their country based on a standardised study 
protocol developed by ECDC.5 These national PPSs took place during one of the following 
periods: May–June 2011, September–October 2011, May–June 2012, or September–
November 2012. These periods were chosen to fall outside winter (when there is a higher 
antimicrobial use) and outside summer (when there is a lower staffing rate). The national 
PPSs could be performed according to two methods for data collection: a patient-based 
protocol (referred to as the standard protocol) and a unit-based protocol (light protocol). In 
the standard protocol, demographic and risk factor data were collected for every single 
patient. In the light protocol, denominator data were aggregated at the ward level and for 
each specialty (e.g. total of paediatric surgical patients in the ward), and demographic and 
risk factor data were collected individually for each patient with at least one HAI. Data were 
collected by locally trained healthcare workers and submitted to the national PPS 
coordinators, who themselves submitted the data to ECDC. Additional information about the 
ECDC PPS methodology is available in the ECDC PPS report.3 
As part of the ECDC PPS, all children hospitalised in general paediatrics, in paediatric 
surgery, in a paediatric intensive care unit (PICU), in a neonatal care unit, or in a neonatal 
intensive care unit (NICU) were eligible for the PPS if admitted to the ward before 8:00 AM 
on the day of the survey. Children in day-care wards, long-term-care wards, and healthy 
newborns in maternity wards were excluded from the PPS. Data on patients and HAIs were 
retrieved from patient charts and/or other sources (e.g. hospital information system, 
laboratory database) using standardised data collection forms. 
 HAI prevalence was defined as the proportion of paediatric patients with one or more 
HAI among all paediatric patients. HAI data included the type of HAI according to the HAI 
case definitions,5 the date of onset of the HAI, the presence of invasive devices in the 48 
hours before onset of HAI (for LRTIs, UTIs, and BSIs), the isolated microorganisms and 
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selected antimicrobial resistance data. HAI definitions were based on definitions from the 
German Krankenhaus Infektions Surveillance System (KISS) for neonatal infections,6 and 
from the European Society for Clinical Microbiology and Infectious Diseases Study Group for 
Clostridium difficile (ESGCD) for Clostridium difficile infections.7 The definitions of HAIs used 
for paediatric patients are shown in the supplementary table 1. 
 HAI prevalence and distribution of HAI-types among countries and clinical settings 
were the main outcomes and were calculated based on the combined data obtained 
following the standard and the light protocol. To report HAI prevalence and its corresponding 
95% confidence intervals (95%CIs), we used two nested levels of clustering at the hospital 
level and country level to take into account the correlation of data within the levels. Patient 
characteristics, exposure, and clinical settings were secondary outcomes and a descriptive 
analysis was performed on data obtained following the standard protocol. Categorical 
variables were compared using the chi-square test; continuous variables were summarized 
as means or medians and compared using the Student’s t-test or the Wilcoxon’s rank sum 
test where appropriate. Adjusted risk factor analysis was performed on data obtained 
following the standard protocol. To estimate the risk factors for HAI, we used a generalised 
linear mixed-effects model with a logit link function. In the multivariable model, we adjusted 
for the following confounders: gender, age stratified into five age groups (<1 month, 1-11 
months, 1-4 years, 5-10 years, ≥11 years), McCabe score (nonfatal, ultimately fatal, i.e. fatal 
outcome within the next 5 years, rapidly fatal, i.e. fatal outcome within the next 6 months),14 
use of any invasive medical device (central catheter, peripheral line, urinary catheter, 
ventilation) alone or combined, and length of hospital stay defined as the days before and 
including the day of the point prevalence survey for controls (or as before and including the 
first day of HAI for HAI cases) and stratified into four categories (<4 days, 4-7 days, 8-14 
days, >14 days). Patients with missing data were not included in this analysis. No consistent 
information was available about the size of the paediatric settings or whether the participating 
hospitals were free standing children’s hospitals. As a proxy we stratified the analysis 
according to the number of children enrolled in the survey by category: ≤25 children, 26-40 
children, 41-70 children, >70 children. 
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Ethical approval was at the discretion of each national public health and government 
body in charge each national PPS. Anonymised patient and hospital level data were shared 
with ECDC.  
 
Role of the funding source: The ECDC PPS 2011-2012 was coordinated by ECDC and 
performed by each EU/EEA Member State with its own funding. ECDC funded several 
meetings of experts and Member State contact points to develop the methodology, provide 
training, and discuss results. No specific funding was provided by ECDC for this analysis of 
paediatric data. The Member States had no role in study design, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication. 
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Results 
Of the 231,459 patients included in the final ECDC PPS database, 17,273 (7.5%) were 
children and were reported by 29 countries. They were hospitalised in 1356 wards of 618 
hospitals, of which 148 (23.9%) were primary hospitals, 260 (42.1%) secondary hospitals, 
146 (23.6%) tertiary hospitals, 39 (6.3%) specialised hospitals, and 25 (4.1%) with unknown 
status. Most children were hospitalised in general paediatric wards (8298, 48.0%), followed 
by neonatal units (4467, 25.9%), NICUs (2283, 13.2%), paediatric surgery wards (1437, 
8.3%), and PICUs (788, 4.6%). The country-wide distribution of clinical settings is shown in 
figure 1 (left-hand side). Of the 17,273 children, 16,237 (94.0%) were registered following the 
standard protocol, and 1036 (6.0%) following the light protocol. Patient characteristics are 
summarized in table 1. The distribution of children by age groups was as follows: <1 month: 
5587 (34.4%); 1-11 months: 4024 (24.8%); 1-4 years: 2970 (18.3%); 5-10 years: 1753 
(10.8%); ≥11 years: 1864 (11.5%); data about age were missing for 39 (0.2%) children. In 
the unadjusted descriptive analysis, children with HAI were of lower age, were more likely to 
have a rapidly fatal McCabe score, had previous surgery, had any invasive device in place 
48 hours before HAI or on the day of survey, had prolonged length of stay up to the survey, 
and were more likely to be hospitalised in a PICU or a NICU (table 1).  
A total of 770 HAIs were reported in 726 children corresponding to an HAI prevalence 
[95%CI] of 4.2% [3.7-4.8]. The country range was 1.2% to 10.4% (figure 1; supplementary 
table 2). Three countries had a HAI prevalence above the upper limit of the 95%CI and two 
countries had a HAI prevalence below the lower limit of the 95%CI (figure 1). PICUs (15.5% 
[11.6-20.3]) and NICUs (10.7% [9.0-12.7]) were the two clinical settings with the highest HAI 
prevalence, followed by neonatology (3.5% [2.8-4.5]), paediatric surgery (3.4% [2.3-4.9]), 
and general paediatrics (1.8% [1.4-2.4]). Predicted HAI prevalence stratified by clinical 
settings and taking into account the number of children contributed to the database is 
summarized in supplementary table 3. 
Paediatric centres contributing >70 children to the database had the highest HAI 
prevalence (6.5% [6.1-6.8]) compared to centres contributing 41-70 (4.9% [4.6-5.2]), 26-40 
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(3.2% [3.0-3.5]), and ≤25 children (2.4% [2.2-2.5]) to the database, respectively. Paediatric 
patients from centres contributing more children also had less favourable McCabe scores 
(4.0% rapidly fatal cases), were more likely to be hospitalised in NICU (16.8%) or PICU 
6.9%), had more invasive medical devices (49.6% children with ≥1 device), and were 
hospitalised longer (21.2% children hospitalised >14 days) (supplementary table 4).  
The HAI prevalence per age group was as follows: <1 month: 5.1% (95%CI: 4.5-5.7); 
1-11 months: 6.5% (5.7-7.2); 1-4 years: 2.2% (1.6-2.7) 5-10 years: 2.1% (1.4-2.8); ≥11 years: 
2.8% (2.0-3.5). BSI was the most common type of HAI (44.6% [41.0-48.1]), followed by LRTI 
(22.2% [19.3-25.2]), GI (8.3% [6.4-10.3]), eye ear nose and throat infection (EENT) (7.1% 
[5.3-9.0]), UTI (4.8% [3.3-6.3]), and SSI (4.4% [3.0-5.9]). The distribution of the different 
types of HAIs varied depending on the country and this could not be explained by the 
distribution of the different paediatric settings (supplementary figure 1; supplementary table 
5). Most HAIs (592/770, 76.9%) were identified in infants in their first 11 months of life. BSI 
was the most common type of HAI in neonates (57.1%), in the first 11 months of life (44.3%), 
between 1-4 years of age (25.4%), and ≥11 years of age (25.9%) (figure 2). Only in the age 
group of 5-10 years of age were LRTIs (26.2%) more common than BSIs (21.4%). UTIs were 
uncommon in neonates (0.7%), but contributed to 6.9–9.9% HAIs in older age groups. SSIs 
became gradually more frequent in older age groups.  
Table 2 summarizes the independent risk factors for having at least one HAI at the 
time of the survey. Compared to neonates, older age groups, particularly after the first 11 
months of life, were less likely to suffer from a HAI. Both ultimately and rapidly fatal McCabe 
scores were significantly associated with having at least one HAI. Length of stay up to the 
day of the survey was a time-dependent risk for HAI for all time categories (4-7 days, 8-14 
days, >14 days) compared to the first category (<4 days). Having one or more invasive 
medical devices in place (within 48h before onset of HAI) was highly associated with having 
a HAI.  
A total of 392 microorganisms were reported in 342 (44.4%) of the 770 HAIs: 343 
(87.5%) were bacteria, 28 (7.1%) fungi, and 21 (5.4%) viruses. Enterobacteriaceae were the 
most commonly isolated microorganisms (28.8%), followed by coagulase-negative 
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staphylococci (20.9%) and Staphylococcus aureus (10.5%) (table 3). Coagulase-negative 
staphylococci were the most common microorganism in neonates and infants <12 months of 
age (table 3). The proportion of Staphylococcus aureus isolates that were resistant to 
meticillin was 18.8%. The proportions of Enterobacteriaceae isolates that were resistant to 
3rd-generation cephalosporins and to carbapenems were 44.4% and 8.6%, respectively 
(supplementary figure 2). Of the few reported viruses, rotaviruses were the most frequently 
identified (13/21).  
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Discussion 
We performed an analysis of the largest multinational dataset of HAIs in paediatric patients. 
Our results confirmed that the burden of HAIs was the highest in the first year of life and 
demonstrated the importance of BSI as being the most common type of HAI in children from 
all age groups. LRTIs and particularly SSIs were more frequent in older age groups and the 
distribution of HAIs in children aged 5 years or older was close to the distribution of HAIs in 
adults.1, 3, 8, 9 These findings suggest that age-adapted strategies are needed for infection 
prevention and control in paediatric settings, focussing on the prevention of BSI. We 
observed variations in HAI prevalence and the distribution of HAI-types among European 
countries. These variations could neither be explained by the distribution of paediatric 
settings in the database, nor did they follow a geographical pattern. Although the range of 
HAI prevalence (1.2-10.4%) was wide, only a few countries were significant high or low 
outliers. No specific conclusion on the effectiveness of national infection prevention and 
control practices could be drawn from our results. Age as well as ultimately and rapidly fatal 
McCabe scores were identified as independent risk factors for HAI. No information was 
available about the size of the participating paediatric settings or about whether the 
institutions were free-standing children’s hospitals. As a proxy we stratified the analysis by 
the number of enrolled children and found that indeed, hospitals that had enrolled more 
children had a higher HAI prevalence. The low HAI prevalence in the age group <1 month 
was unexpected. A closer look revealed that this was due to the fact that, in the sample of 
paediatric settings that participated in the ECDC PPS, (non-intensive) neonatal units 
contributed 66.2% of the neonatal population. Indeed, most neonates were hospitalised in 
regular non-intensive care neonatology units. This is of interest because, in the published 
literature, studies among preterm neonates in NICUs are more common than studies in other 
neonatal units and thus, may contribute to a perceived high risk for HAI in the neonatal 
population as a whole. However, a number of neonates with prolonged hospital stay were 
classified in the age group of 1-11 months, and thus, contributed to the high prevalence in 
this age group. 
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Very few recent reports of cross-national PPSs including paediatric data have been 
published. Between 1983 and 1987, the World Health Organization conducted a 
multinational PPS in 47 hospitals from 14 countries (Australia, China, Czechoslovakia, 
Denmark, Egypt, Greece, Kuwait, Malaysia, Nepal, Netherlands, Singapore, Spain, Thailand, 
United Kingdom).10 A total of 28,861 patients were included of which 3147 (10.9%) were 
children. The HAI prevalence in the four age groups of children (< 1 month, 1-11 months, 1-4 
years, 5-14 years) were 8.8%, 13.5%, 9.3%, and 6.7%, respectively. More information can 
be obtained from national PPSs. Table 4 summarizes the findings of 14 previously published 
national and multi-national PPS in high-income countries in comparison with that of the 
ECDC PPS 2011/2012.8, 11-24 One PPS was the ECDC pilot survey in 2010.24 Eight national 
PPSs were conducted in a general patient population in which children were included;8, 11, 13, 
15, 17-21 two specifically addressed NICUs;16, 22 and one was performed in general paediatric 
wards.23 One study in the UK and Ireland focused exclusively on LRTIs in children.14 The 
largest paediatric dataset was from a national PPS conducted in France in 2001 and 
included 305,656 patients of which 21,596 (7.1%) were children.18 In this French PPS, the 
prevalence of HAI among children was 2.4% [2.2-2.6%] overall, 1.2% [1.0-1.5%] for 
neonates and 3.3% [3.0-3.6%] for children in non-neonatal settings. The group of neonates 
also included new-borns in maternity units, which may be the reason for the low HAI 
prevalence in this group. In addition, the proportion of laboratory confirmed HAIs (456/562; 
81.1%) was unusually high, which raises concerns about the possible underestimation of HAI 
prevalence, in particular LRTIs and clinical sepsis.  
As in our study, BSI was the most common type of HAI in these other reports (range: 
22.1-52.6%).13, 16, 17, 25 However, although the vast majority of BSIs in our study were reported 
in neonates and infants in their first 11 months of life, the proportion of BSIs among all HAIs 
remained high also in other age groups. LRTIs and SSIs were more frequent in children of 5 
years or older. UTIs were not common and overall less important than GIs and EENTs, 
particularly in older age groups. Our results suggest that neonates and infants requiring 
intensive care are at high risk for HAI. Other reports identified risk factors for HAI similar to 
that identified in our study: young age and surgery,13 presence of an invasive device and 
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prolonged length of stay,25 central venous catheter or mechanical ventilation,19 and again 
young age and an ultimately or rapidly fatal McCabe score.17 In our study, all tested risk 
variables were independently and significantly associated with HAI but the highest effects 
were found for the use of invasive medical devices and for length of stay >14 days up to the 
day of the PPS (or for HAI cases up to the first day of infection) with odds ratios of 15.3 (95% 
CI, 11.9-19.7) and 14.9 (95% CI, 11.0-20.1), respectively.  
The two most common groups of microorganisms in HAI among children in our study 
were Enterobacteriaceae and coagulase-negative staphylococci, which was similar to 
findings in France (Enterobacteriaceae: 21.9%; coagulase-negative staphylococci: 21.9%),18 
Switzerland (Enterobacteriaceae; 50.0%; coagulase-negative staphylococci: 29.2%),17 and 
the USA (Enterobacteriaceae: 25.6%; coagulase-negative staphylococci: 31.6%).16 In a 
Mexican study, the most common pathogen in HAI among children was Klebsiella 
pneumoniae (31.0%).26 The proportion of meticillin-resistant Staphylococcus aureus (MRSA) 
in HAI in children in the French PPS was 26.7%.18 No MRSA was reported in paediatric 
patients in the Swiss study.17 The relatively low number of microbiologically documented 
HAIs was due to the high proportion of HAI-types that did not require microbiology testing, 
such as clinical sepsis or pneumonia. 
Our study has some limitations. First, data were collected by many individuals in 
different countries. Training was provided in all participating countries but data validation 
based on samples of sufficient size was not possible due to resource limitations. Second, the 
results of this study may not be representative for the paediatric acute care patient 
populations in all European countries. Future PPSs should take representativeness of 
subgroups of paediatric patients into account. Third, conducting the national PPSs at four 
different time periods may have introduced bias in the case-mix of patients, in particular 
because they took place in different seasons and over two years. However, these time 
periods of the ECDC PPS were outside winter and summer seasons where paediatric 
settings are particularly prone to either low or high ward occupancy. Fourth, the data 
collection forms had limited fields for paediatric data. For example, more information about 
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birth weight and prematurity would have been needed to adjust for relevant risk factors for 
HAI in neonates, specific information about the paediatric settings (e.g. free standing 
children’s hospital, level of care, case-mix), that were missing in the ECDC PPS 2011/2012 
database. Fifth, only microbiology data available on the day of the PPS was included and 
thus, both the distribution of microorganisms and antibiotic resistance data may not be 
representative. Although having incomplete microbiology data does not interfere directly with 
identifying a HAI, it may have consequences in sub-categorising the type of infection. Sixth, 
healthy newborns may have been coded as belonging to a non-intensive neonatal unit, 
instead of being newborns in gynaecology-obstetrics. We assume that this proportion was 
low but may have had an impact on the overall prevalence of HAI in neonatal wards. 
Seventh: Calculating weighted EU/EEA estimates as reported in the ECDC PPS report for 
the overall PPS3 was not possible because no specific information on the number of 
paediatric beds and patient-days in the countries were available.  
Our analysis of paediatric data from the ECDC point prevalence survey 2011/2012 
represents the largest multi-national study on HAI prevalence in children conducted so far. 
Despite its limitations, it provides detailed information on the prevalence and distribution of 
HAIs among hospitalised children in Europe. Our results show that the prevalence of HAIs in 
NICUs and PICUs in Europe remains unacceptably high. BSIs in neonates and children are 
associated with a high mortality and long-term adverse neurological outcomes.27 Prevention 
of HAIs in children in Europe would require a multi-national quality improvement programme, 
with a focus on NICUs and PICUs and on healthcare-associated BSIs.  
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Table 1. Patient characteristics, exposures and clinical areas – Paediatric data, standard protocol, ECDC point prevalence survey 2011-2012 
 
 All 
(N = 16,237) 
Without HAI  
(N = 15,511) 
With HAI  
(N = 726) 
P-value 
Patient characteristics     
Female gender, % [95%CI] 46.0 [45.3-46.8] 46.2 [45.4-47.0] 42.5 [38.8-46.2] 0.055 
Age (months), median [IQR]     3 [0-48]     3 [0-48]     1 [0-7] <0.001 
Neonates, % [95%CI] 33.2 [32.5-33.9] 32.9 [32.2-33.6] 39.8 [36.1-43.4] <0.001 
 Rapidly fatal McCabe score, % [±SD]  0.7 [0.6-0.8]  0.6 [0.4-0.7]  3.9 [2.4-5.3] <0.001 
Exposures     
Surgery*, % [95%CI]   9.1 [8.7-9.6]  8.5 [8.0-8.9] 23.9 [27.1] <0.001 
Central catheter*, % [95%CI]   7.1 [6.7-7.5]  5.8 [5.4-6.1] 36.9 [33.3-40.5] <0.001 
Peripheral line*, % [95%CI]  38.7 [37.9-39.4] 37.4 [36.6-38.2] 67.2 [63.8-70.7] <0.001 
Urinary catheter*, % [95%CI]   2.2 [2.0-2.4]  1.8 [1.6-2.0] 11.6 [9.2-14.0] <0.001 
Ventilation*, % [95%CI]   3.0 [2.8-3.3]  2.2 [1.9-2.5] 22.0 [19.0-25.1] <0.001 
Length of stay (days)**, median [IQR]     4 [2-8]     4 [2-8]    12 [6-26] <0.001 
Clinical areas     
Paediatric intensive care, % [95%CI]  3.6 [3.3-3.9]  3.1 [2.8-3.4] 15.3 [12-6-18.0] <0.001 
Neonatal intensive care, % [95%CI] 11.2 [10.7-11.7] 10.4 [9.9-10.9] 27.9 [24.6-31.2] <0.001 
Neonatology, % [95%CI] 27.8 [27.1-28.4] 27.7 [27.0-28.4] 27.9 [24.6-31.2] 0.930 
Paediatric surgery, % [95%CI]  8.1 [7.6-8.5]  8.1 [7.7-8.5]  7.2 [5.2-9.1] 0.364 
General paediatrics, % [95%CI] 49.4 [48.6-50.2] 50.6 [49.8-51.4] 21.7 [18.7-24.8] <0.001 
 
*Before or on the day of the point prevalence survey 
**Before and including the day of the point prevalence survey 
95%CI: 95% confidence interval; ECDC: European Centre for Disease Prevention and Control; HAI: healthcare-associated infection; IQR: 
interquartile range  
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Table 2. Independent risk factors for HAI – Multivariable model of paediatric data, standard protocol, ECDC point prevalence survey 2011-2012 
 
 OR 95%CI P-value 
Gender     
Girl 1.0 - - 
Boy 1.1 1.0-1.4 0.150 
Age group    
<1 month 1.0 - - 
1-11 months 0.6 0.5-0.7 <0.001 
1 – 4 years 0.2 0.2-0.3 <0.001 
5 – 10 years 0.2 0.1-0.3 <0.001 
≥11 years 0.2 0.2-0.3 <0.001 
McCabe classification    
Nonfatal 1.0 - - 
Ultimately fatal 2.3 1.3-4.1 0.003 
Rapidly fatal 2.5 1.7-3.6 <0.001 
Length of stay (days)*    
<4 1.0 - - 
4-7 3.3 2.4-4.5 <0.001 
8-14 6.7 4.9-9.1 <0.001 
>14 14.9 11.0-20.1 <0.001 
Presence of at least one invasive medical device 
No 1.0 - - 
Yes 15.3 11.9-19.7 <0.001 
 
*For cases: before and including the first day of HAI. For controls: before and including the day of the point prevalence survey. 
95%CI: 95% confidence interval; ECDC: European Centre for Disease Prevention and Control; HAI: healthcare-associated infection; OR: odds ratio 
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Table 3. Identified microorganisms – Paediatric data, ECDC point prevalence survey 2011-2012 
 
Microorganism 
  Age group    
All  <1 month 1-11 months 1-4 years 5-10 years ≥11 years 
Coagulase-negative staphylococci 82 (21.0%) 33 (31.4%) 38 (21.3%) 3 (7.0%) 1 (3.1%) 7 (21.9%) 
Staphylococcus aureus 41 (10.5%) 15 (14.3%) 14 (7.9%) 4 (9.3%) 4 (12.5%) 4 (12.5%) 
Escherichia coli 37 (9.5%) 7 (6.7%) 17 (9.6%) 4 (9.3%) 4 (12.5%) 5 (15.6%) 
Klebsiella spp. 37 (9.5%) 6 (5.7%) 21 (11.8%) 7 (16.3%) 2 (6.3%) 1 (3.1%) 
Enterobacter spp. 27 (6.9%) 14 (13.3%) 10 (5.6%) 2 (4.7%) 0 (0.0%) 1 (3.1%) 
Pseudomonas aeruginosa 26 (6.7%) 3 (2.9%) 10 (5.6%) 7 (16.3%) 4 (12.5%) 2 (6.3%) 
Candida spp.* 23 (5.9%) 3 (2.9%) 12 (6.7%) 3 (7.0%) 1 (3.1%) 4 (12.5%) 
Viruses 21 (5.4%) 3 (2.9%) 13 (7.3%) 4 (9.3%) 1 (3.1%) 0 (0.0%) 
Enterococcus spp. 20 (5.1%) 5 (4.8%) 12 (6.7%) 2 (4.7%) 1 (3.1%) 0 (0.0%) 
Streptococcus spp. 18 (4.6%) 6 (5.7%) 5 (2.8%) 1 (2.3%) 4 (12.5%) 2 (6.3%) 
Stenotrophomonas malthophilia* 12 (3.1%) 0 (0.0%) 8 (4.5%) 1 (2.3%) 3 (9.4%) 0 (0.0%) 
Serratia marcescens 8 (2.1%) 4 (3.8%) 3 (1.7%) 1 (2.3%) 0 (0.0%) 0 (0.0%) 
Acinetobacter baumannii 7 (1.8%) 3 (2.9%) 4 (2.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Clostridium difficile 4 (1.0%) 0 (0.0%) 1 (0.6%) 1 (2.3%) 2 (6.3%) 0 (0.0%) 
Haemophilus influenzae 4 (1.0%) 0 (0.0%) 1 (0.6%) 1 (2.3%) 1 (3.1%) 1 (3.1%) 
Moraxella catarrhalis 4 (1.0%) 0 (0.0%) 2 (1.1%) 1 (2.3%) 1 (3.1%) 0 (0.0%) 
Proteus mirabilis 4 (1.0%) 0 (0.0%) 1 (0.6%) 1 (2.3%) 1 (3.1%) 1 (3.1%) 
Aspergillus fumigatus 3 (0.8%) 0 (0.0%) 2 (1.1%) 0 (0.0%) 0 (0.0%) 1 (3.1%) 
Other 12 (3.1%) 3 (2.9%) 4 (2.2%) 0 (0.0%) 2 (6.3%) 3 (9.4%) 
Total 390 (100.0%) 105 (100.0%) 178 (100.0%) 43 (100.0%) 32 (100.0%) 32 (100.0%) 
 
*Missing data about age for one isolate 
ECDC: European Centre for Disease Prevention and Control 
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Table 4. Paediatric data of national and multi-national prevalence surveys in high-income countries 
 
Survey Setting Patients 
(N) 
Children 
(N) 
Prevalence, by age group§ 
All  
(% [95%CI])* 
Neonates 
 (% [95%CI])* 
Infants 
(% [95%CI])* 
 Children 
(% [95%CI])* 
Moro, Italy, 1983 11 Adult/children 34,577 3099 7.7 [6.8-8.7]  -  11.5 [9.6-13.5] 5.8 [4.8-6.9] 
Campins, Spain, 1990
† 12, 13 Adult/children 38,489 4081 8.5 [8.2-8.7] - - 8.5 [7.6-9.3] 
Kelsey, UK/Ireland, 1993/1994 14 LRTI/children 6183 6183 1.3 [1.1-1.7]  -  1.7 [1.3-2.2] 0.7 [0.4-1.2] 
Gikas, Greece, 1999 15 Adult/children 3925 332 9.9 [6.9-13.7 ]  -  19.7 [13.2-27.7] 3.9 [1.7-7.5] 
Sohn, USA, 1999 16 NICU 827 827 11.4 [9.3-13.8] 11.4 [9.3-13.8]  -   -  
Mühlemann, Switzerland, 2000 17 Adult/children 520 520 6.7 [4.7-9.2] 6.9 [3.0-13.1] 10.1 [6.2-15.1] 4.7 [2.6-7.6] 
Branger, France, 2001 18 Adult/children 305,656 21,596 2.4 [2.2-2.6 ] 1.2 [1.0-1.5 ]  -  3.3 [3.0-3.6 ] 
Gravel, Canada, 2002
†
 
19, 20
 Adult/children 6747 997 10.0 [9.4-10.8] 18.5 [13.9-23.9] 2.2 [1.0-4.4] 8.0 [6.4-9.9] 
Valinteliene, Lithuania, 2003/2005/2007 21 Adult/children 10,102 3733 3.3 [2.7-3.9] - - - 
Sarvikivi, Finland, 2008/2009 22 NICU 2562 2562 6.4 [5.4-7.4] 6.4 [5.4-7.4]  -   -  
Rutledge, Canada, 2009 23 Children 1353 1353 9.2 [7.7-10.9] 4.8 [2.9-7.4]  14.0 [10.7-17.8] 10.9 [7.4-15.4] 
Zarb, Europe, 2010 
24
 Adult/children 19,888 1024 7.1 [6.7-7.4] - 7.8 [6.0-9.9] 3.7 [2.6-5.1] 
Magill, USA, 2011 8 Adult/children 11,282 1611 3.4 [2.6-4.4]  -  3.1 [2.2-4.3]  4.1 [2.5-6.4] 
ECDC PPS 2011/2012‡ Adult/children 231,459 16,237 4.2 [3.7-4.8] 5.1% [4.5-5.7] 6.5 [5.7-7.2] 2.3 [2.0-2.7] 
 
*95% confidence intervals were calculated from published data  
†Added numbers from separate publications of adult and children data of the same national prevalence survey 
‡Data from the standard protocol 
§Age groups: neonates: 1 month of life; infants: <1 year of life; children: 1 year and older 
95%CI: 95% confidence interval; LRTI: lower respiratory tract infection; NICU: neonatal intensive care unit 
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Figure 1. Prevalence of children with one or more healthcare-associated infections and clinical settings – Paediatric data, ECDC point prevalence 
survey 2011-2012 
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Figure 2. Distribution of healthcare-associated infections in children, by age group – Paediatric data, standard protocol, ECDC point prevalence 
survey 2011-2012 
 
 
 
